Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews

Written by Emily J. Thompson, Senior Investment Analyst

ITCI%

Source: Benzinga

Updated: Apr 02 2025

0mins

Source: Benzinga

Analyst Ratings Overview: Intra-Cellular Therapies received mixed analyst ratings, with no bullish or bearish sentiments noted recently; the average 12-month price target has increased to $126.67, reflecting a positive shift in expectations.
Financial Performance Insights: The company reported significant revenue growth of approximately 51.49% over three months, but its net margin, return on equity, and return on assets are below industry averages, indicating challenges in profitability and asset management.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Chipotle vs Dutch Bros: Growth vs Valuation Showdown

XRP Drops 40% from July Peak; Ripple's Products Face Adoption Challenges

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch